Skip to main content
Clinical Trials/CTRI/2021/08/035342
CTRI/2021/08/035342
Completed
未知

Pleiotropic effects of Teneligliptin versus Glimepiride as add on therapy to Metformin on Inflammatory biomarker hsCRP and Insulin resistance : An open-labelled randomized controlled trial

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
All India Institute of Medical Sciences Rishikesh
Enrollment
70
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 20, 2023
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Type 2 Diabetes patients not controlled by Metformin alone (with HbA1C \> 7% )
  • Age \> 20 years and \< 60 years
  • Both male and female gendersÂ

Exclusion Criteria

  • Type 2 Diabetes patients who are already on any DPP4 inhibitors \& Metformin combination therapy or on Insulin or any other incretin based therapy or any hypoglycaemic agents
  • Patients with any acute inflammatory/ infective condition with CRP \> 10 mg/L and any history of acute infection/ inflammation in past 3 monthsÂ
  • Patients with chronic inflammatory conditions, autoimmune diseases, Neoplasia
  • Patients with serious macrovascular complications such as acute MI, angina or stroke within six months of enrolment
  • Type 1 Diabetes patients or any other form of diabetes
  • Pregnant or Breastfeeding females

Outcomes

Primary Outcomes

Not specified

Similar Trials